RU2004120292A - Фармацевтическая композиция, содержащая агонисты 5ht1- рецепторов - Google Patents
Фармацевтическая композиция, содержащая агонисты 5ht1- рецепторов Download PDFInfo
- Publication number
- RU2004120292A RU2004120292A RU2004120292/15A RU2004120292A RU2004120292A RU 2004120292 A RU2004120292 A RU 2004120292A RU 2004120292/15 A RU2004120292/15 A RU 2004120292/15A RU 2004120292 A RU2004120292 A RU 2004120292A RU 2004120292 A RU2004120292 A RU 2004120292A
- Authority
- RU
- Russia
- Prior art keywords
- headache
- pharmaceutical composition
- composition according
- weight
- sumatriptan
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (9)
1. Фармацевтическая композиция в виде твердой дозированной формы для перорального введения, с пленочным покрытием, которая распадается при введении и распределяется в желудочно-кишечном тракте, содержащая суматриптан или его фармацевтически приемлемую соль или сольват в качестве активного ингредиента, в которой содержание суматриптана, выраженное в виде массы его основания, составляет от 20 мг до 150 мг, включающая основный компонент шипучей пары, разрыхляющий агент и нерастворимый наполнитель, причем основный компонент составляет от примерно 5 до примерно 50% по массе, разрыхляющий агент составляет от примерно 0,5 до примерно 10% по массе и нерастворимый наполнитель составляет от примерно 35 до примерно 80% по массе, причем указанный нерастворимый наполнитель включает набухающий агент, который составляет от примерно 1 до примерно 99% по массе из расчета сухого веса дозированной формы, и в которой более чем примерно 70%, активного ингредиента растворяется в искусственном желудочном соке (ИЖС) в течение 5 мин в аппарате USPII при скорости вращения лопастей примерно 10 об/мин.
2. Фармацевтическая композиция по п.1, в которой суматриптан присутствует в виде его фармацевтически приемлемой соли, которая обеспечивает, таким образом, в водной среде компонент кислого характера.
3. Фармацевтическая композиция по п.1 или 2, в которой основный компонент составляет от примерно 7 до примерно 20% по массе.
4. Фармацевтическая композиция по п.1 или 2, которая дополнительно содержит кислотный компонент шипучей пары, где указанный кислотный компонент (включая фармацевтически приемлемое производное суматриптана, если оно действует таким же образом) составляет до примерно 55% по массе.
5. Фармацевтическая композиция по любому из п.1 или 2, в которой основный компонент шипучей пары представляет бикарбонат натрия, разрыхляющий агент представляет натрийкроскармелозу, и нерастворимый наполнитель представляет безводный двухосновный фосфат кальция или микрокристаллическую целлюлозу или их смесь.
6. Фармацевтическая композиция по п.1 или 2, в которой суматриптан присутствует в форме его сукцинатной соли (1:1).
7. Фармацевтическая композиция по любому из п.1 или 2 в форме таблетки.
8. Фармацевтическая композиция по п.1 или 2, для применения в лечении состояний, связанных с головной болью, таких как приступообразная головная боль с периодическими рецидивами, хроническая пароксизмальная гемикрания, головная боль, связанная с сосудистыми нарушениями, головная боль, связанная с веществами или их отменой, иррадиирующая (реактивная) головная боль, головная боль, связанная с артериальным давлением, и, в особенности, мигрень.
9. Применение фармацевтической композиции по п.1 или 2, для изготовления препарата для лечения состояний, связанных с головной болью, таких как приступообразная головная боль с периодическими рецидивами, хроническая пароксизмальная гемикрания, головная боль, связанная с сосудистыми нарушениями, головная боль, связанная с веществами или их отменой, иррадиирующая головная боль, головная боль, связанная с артериальным давлением, и, в особенности, мигрень.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0129117.8 | 2001-12-05 | ||
| GBGB0129117.8A GB0129117D0 (en) | 2001-12-05 | 2001-12-05 | Pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2004120292A true RU2004120292A (ru) | 2005-04-10 |
| RU2285526C2 RU2285526C2 (ru) | 2006-10-20 |
Family
ID=9927051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004120292/15A RU2285526C2 (ru) | 2001-12-05 | 2002-12-04 | Фармацевтическая композиция, содержащая агонист 5ht1-рецепторов |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US20050032867A1 (ru) |
| EP (2) | EP1450770B1 (ru) |
| JP (1) | JP3699969B2 (ru) |
| KR (1) | KR100591237B1 (ru) |
| CN (1) | CN1289069C (ru) |
| AR (1) | AR037627A1 (ru) |
| AT (1) | ATE291900T1 (ru) |
| AU (1) | AU2002358602B2 (ru) |
| BR (1) | BR0214497A (ru) |
| CA (1) | CA2469019C (ru) |
| CO (1) | CO5580741A2 (ru) |
| DE (1) | DE60203537T2 (ru) |
| ES (1) | ES2236608T3 (ru) |
| FI (1) | FI20022128A (ru) |
| GB (1) | GB0129117D0 (ru) |
| HK (1) | HK1069111A1 (ru) |
| HU (1) | HU229313B1 (ru) |
| IL (1) | IL161997A (ru) |
| IS (1) | IS2481B (ru) |
| MX (1) | MXPA04005420A (ru) |
| MY (1) | MY129314A (ru) |
| NO (1) | NO329896B1 (ru) |
| NZ (1) | NZ532829A (ru) |
| PL (1) | PL194702B1 (ru) |
| PT (1) | PT1450770E (ru) |
| RU (1) | RU2285526C2 (ru) |
| TW (1) | TWI240638B (ru) |
| WO (1) | WO2003047552A2 (ru) |
| ZA (1) | ZA200403849B (ru) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
| US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
| US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
| WO2004089365A1 (en) | 2003-04-11 | 2004-10-21 | Pfizer Limited | Pharmaceutical combination comprising eletriptan and sodium bicarbonate |
| EP1633402A2 (en) * | 2003-06-06 | 2006-03-15 | Glaxo Group Limited | Pharmaceutical composition |
| US8216610B2 (en) | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
| US20080287456A1 (en) * | 2004-05-28 | 2008-11-20 | Imaginot Pty Ltd | Oral Therapeutic Compound Delivery System |
| US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
| US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
| MX2007004741A (es) | 2004-10-21 | 2007-09-07 | Eurand Pharmaceuticals Ltd | Composiciones farmaceuticas con sabor enmascarado con formadores de poro gastrosolubles. |
| US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
| JP2009517346A (ja) * | 2005-11-28 | 2009-04-30 | イメイジノット ピーティーワイ エルティーディー | 治療用化合物の経口送達系 |
| CN101431895A (zh) * | 2006-05-01 | 2009-05-13 | 卡普里康制药公司 | 新颖的曲坦制剂和制备它们的方法 |
| WO2008039358A2 (en) * | 2006-09-30 | 2008-04-03 | Capricorn Pharma Inc. | Resin-complex granulation for water-soluble drugs and associated methods |
| TWI471146B (zh) | 2009-12-02 | 2015-02-01 | Aptalis Pharma Ltd | 菲索特芬那定（ｆｅｘｏｆｅｎａｄｉｎｅ）微膠囊及包含其之組合物 |
| US11364225B2 (en) | 2019-08-21 | 2022-06-21 | Bn Intellectual Properties, Inc. | Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9027827D0 (en) * | 1990-12-21 | 1991-02-13 | Glaxo Laboratoires | Pharmaceutical compositions |
| US5468504A (en) * | 1990-12-21 | 1995-11-21 | Laboratoires Glaxo S.A. | Effervescent pharmaceutical compositions |
| GB9104890D0 (en) * | 1991-03-08 | 1991-04-24 | Glaxo Group Ltd | Compositions |
| US5460972A (en) * | 1991-04-08 | 1995-10-24 | Research Foundation Of The State University Of New York | Ionized magnesium2+ concentrations in biological samples |
| US6649186B1 (en) * | 1996-09-20 | 2003-11-18 | Ethypharm | Effervescent granules and methods for their preparation |
| GB9704524D0 (en) * | 1997-03-05 | 1997-04-23 | Smithkline Beecham Plc | Composition |
| GB9706089D0 (en) * | 1997-03-24 | 1997-05-14 | Scherer Ltd R P | Pharmaceutical composition |
| AU2640599A (en) * | 1998-02-26 | 1999-09-15 | Banyu Pharmaceutical Co., Ltd. | An orally disintegrating composition and its manufacturing method |
| US6350470B1 (en) * | 1998-04-29 | 2002-02-26 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
| US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| CA2392810A1 (en) * | 1999-12-01 | 2001-06-07 | Natco Pharma Limited | A rapid acting freeze dired oral pharmaceutical composition for treating migraine |
| US20020001617A1 (en) * | 2000-05-26 | 2002-01-03 | Chang-Hyun Lee | Rapidly disintegrating tablet and process for the manufacture thereof |
| US20030008005A1 (en) * | 2001-07-05 | 2003-01-09 | R.T. Alamo Ventures, Inc. | Sublingual administration of dihydroergotamine for the treatment of migraine |
-
2001
- 2001-12-05 GB GBGB0129117.8A patent/GB0129117D0/en not_active Ceased
-
2002
- 2002-12-03 FI FI20022128A patent/FI20022128A/fi not_active Application Discontinuation
- 2002-12-03 NO NO20025805A patent/NO329896B1/no not_active IP Right Cessation
- 2002-12-03 MY MYPI20024534A patent/MY129314A/en unknown
- 2002-12-03 AR ARP020104674A patent/AR037627A1/es unknown
- 2002-12-03 TW TW091134979A patent/TWI240638B/zh not_active IP Right Cessation
- 2002-12-04 KR KR1020047008687A patent/KR100591237B1/ko active IP Right Grant
- 2002-12-04 ES ES02792887T patent/ES2236608T3/es not_active Expired - Lifetime
- 2002-12-04 US US10/497,749 patent/US20050032867A1/en not_active Abandoned
- 2002-12-04 RU RU2004120292/15A patent/RU2285526C2/ru not_active IP Right Cessation
- 2002-12-04 DE DE60203537T patent/DE60203537T2/de not_active Expired - Lifetime
- 2002-12-04 PT PT02792887T patent/PT1450770E/pt unknown
- 2002-12-04 CA CA002469019A patent/CA2469019C/en not_active Expired - Lifetime
- 2002-12-04 IL IL16199702A patent/IL161997A/xx active IP Right Grant
- 2002-12-04 HU HU0402178A patent/HU229313B1/hu unknown
- 2002-12-04 PL PL02370669A patent/PL194702B1/pl unknown
- 2002-12-04 EP EP02792887A patent/EP1450770B1/en not_active Expired - Lifetime
- 2002-12-04 MX MXPA04005420A patent/MXPA04005420A/es active IP Right Grant
- 2002-12-04 JP JP2003548808A patent/JP3699969B2/ja not_active Expired - Lifetime
- 2002-12-04 BR BR0214497-2A patent/BR0214497A/pt not_active Application Discontinuation
- 2002-12-04 CN CNB028244184A patent/CN1289069C/zh not_active Expired - Fee Related
- 2002-12-04 NZ NZ532829A patent/NZ532829A/en not_active IP Right Cessation
- 2002-12-04 WO PCT/EP2002/013715 patent/WO2003047552A2/en active IP Right Grant
- 2002-12-04 AT AT02792887T patent/ATE291900T1/de active
- 2002-12-04 EP EP05075288A patent/EP1527773A1/en not_active Withdrawn
- 2002-12-04 AU AU2002358602A patent/AU2002358602B2/en not_active Expired
-
2004
- 2004-05-19 ZA ZA2004/03849A patent/ZA200403849B/en unknown
- 2004-06-03 IS IS7293A patent/IS2481B/is unknown
- 2004-06-03 CO CO04052110A patent/CO5580741A2/es active IP Right Grant
-
2005
- 2005-02-28 HK HK05101699A patent/HK1069111A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004120292A (ru) | Фармацевтическая композиция, содержащая агонисты 5ht1- рецепторов | |
| JPH10511407A (ja) | 高用量難溶性薬物用持続放出マトリックス | |
| PT1441713E (pt) | Comprimidos de tamsulosina de libertação modificada. | |
| WO2002096406A1 (fr) | Compositions medicinales | |
| BRPI0717916A2 (pt) | "forma de dosagem sólida para liberação modificada e método para a liberação modificada de ibuprofeno" | |
| KR20110097829A (ko) | 낮은 ｐＨ에서 불량한 수용해도를 갖는 이온화가능한 활성제의 제어 방출을 위한 고체 조성물, 및 그의 사용 방법 | |
| PT1945186E (pt) | Composições farmacêuticas orais sólidas para dosagem uma vez ao dia contendo pregabalina, um agente de formação de matriz e um agente de intumescimento | |
| PT1017390E (pt) | Comprimido revestido que compreende ácido nicotínico ou um composto metabolizado a ácido nicotínico sob uma forma de libertação prolongada, e um revestimento que contém um inibidor da hmg-coa-redutase sob uma forma de libertação imediata. | |
| JP4608316B2 (ja) | イブプロフェンナトリウムの剤形 | |
| JP2009102339A (ja) | ＨＭＧ−ＣｏＡ還元酵素阻害剤フルバスタチンの徐放性医薬組成物 | |
| JP2006527195A (ja) | トリプタンおよびｎｓａｉｄを含む組成物 | |
| DK146434B (da) | Fremgangsmaade til fremstilling af tabletter eller suppositorier med langvarig frigoerelse | |
| EA014443B1 (ru) | Фармацевтическая композиция (варианты) и способ ее производства | |
| US7700125B2 (en) | Moisture resistant container systems for rapidly bioavailable dosage forms | |
| KR20030048410A (ko) | 경구투여용 조절방출배합물 | |
| US7687542B2 (en) | Rapidly bioavailable tablet and capsule formulations of diclofenac | |
| ES2248850T3 (es) | Formulaciones farmaceuticas que contienen sales de potasiom sodio y tris de oxaprozina. | |
| ES2402206T3 (es) | Formulación de 3-(2-dimetilaminometil-ciclohexil)fenol de efecto retardado | |
| JP6781561B2 (ja) | プロピオン酸系非ステロイド性消炎鎮痛薬を含有した医薬組成物 | |
| KR20040079936A (ko) | 염기성 아미노산 ｉｉ를 함유하는 ｏ-아세틸살리실산의안정한 염 | |
| WO2013052019A1 (en) | Production method for effervescent formulations comprising diclofenac | |
| US20050281873A1 (en) | Universal controlled-release composition | |
| WO2006035313A1 (en) | Solid unit dosage forms of 5-ht1 agonist | |
| US9155704B1 (en) | More palatable, bioequivalent pharmaceutical composition of carprofen | |
| GB2061111A (en) | Long acting pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20141205 |